Next Article in Journal
Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders
Next Article in Special Issue
The Enzymatic and Non-Enzymatic Antioxidant System Response of the Seagrass Cymodocea nodosa to Bisphenol-A Toxicity
Previous Article in Journal
Novel NK1R-Targeted 68Ga-/177Lu-Radioconjugates with Potential Application against Glioblastoma Multiforme: Preliminary Exploration of Structure–Activity Relationships
Previous Article in Special Issue
Bisphenol S Impairs Invasion and Proliferation of Extravillous Trophoblasts Cells by Interfering with Epidermal Growth Factor Receptor Signaling
Review

Endocrine Disruptors and Prostate Cancer

1
Istituto Zooprofilattico Sperimentale del Lazio e della Toscana, Via Appia Nuova 1411, 00178 Rome, Italy
2
Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità (ISS), 00161 Rome, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editors: Nicolas Chevalier and Charlotte Hinault-Boyer
Int. J. Mol. Sci. 2022, 23(3), 1216; https://doi.org/10.3390/ijms23031216
Received: 20 December 2021 / Revised: 18 January 2022 / Accepted: 20 January 2022 / Published: 21 January 2022
(This article belongs to the Special Issue Advances in Endocrine Disruptors)
The role of endocrine disruptors (EDs) in the human prostate gland is an overlooked issue even though the prostate is essential for male fertility. From experimental models, it is known that EDs can influence several molecular mechanisms involved in prostate homeostasis and diseases, including prostate cancer (PCa), one of the most common cancers in the male, whose onset and progression is characterized by the deregulation of several cellular pathways including androgen receptor (AR) signaling. The prostate gland essentiality relies on its function to produce and secrete the prostatic fluid, a component of the seminal fluid, needed to keep alive and functional sperms upon ejaculation. In physiological condition, in the prostate epithelium the more-active androgen, the 5α-dihydrotestosterone (DHT), formed from testosterone (T) by the 5α-reductase enzyme (SRD5A), binds to AR and, upon homodimerization and nuclear translocation, recognizes the promoter of target genes modulating them. In pathological conditions, AR mutations and/or less specific AR binding by ligands modulate differently targeted genes leading to an altered regulation of cell proliferation and triggering PCa onset and development. EDs acting on the AR-dependent signaling within the prostate gland can contribute to the PCa onset and to exacerbating its development. View Full-Text
Keywords: endocrine disruptors; prostate cancer; nuclear androgen receptor; membrane androgen receptors endocrine disruptors; prostate cancer; nuclear androgen receptor; membrane androgen receptors
Show Figures

Figure 1

MDPI and ACS Style

Corti, M.; Lorenzetti, S.; Ubaldi, A.; Zilli, R.; Marcoccia, D. Endocrine Disruptors and Prostate Cancer. Int. J. Mol. Sci. 2022, 23, 1216. https://doi.org/10.3390/ijms23031216

AMA Style

Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D. Endocrine Disruptors and Prostate Cancer. International Journal of Molecular Sciences. 2022; 23(3):1216. https://doi.org/10.3390/ijms23031216

Chicago/Turabian Style

Corti, Margherita, Stefano Lorenzetti, Alessandro Ubaldi, Romano Zilli, and Daniele Marcoccia. 2022. "Endocrine Disruptors and Prostate Cancer" International Journal of Molecular Sciences 23, no. 3: 1216. https://doi.org/10.3390/ijms23031216

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop